A Randomised phase II trial of Enhancement of efficacy of Atezolizumab by Radiotherapy in Metastatic urothelial carcinoma
Latest Information Update: 13 Mar 2024
At a glance
- Drugs Atezolizumab (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- Acronyms RE-ARM
- 06 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 31 Jul 2023 Recruitment completion is expected on 30 September 2024 according to ISRCTN: Current Controlled Trials record
- 31 Jul 2023 Status changed from active, no longer recruiting to recruiting.